Redx hails progress

DRUG development company Redx Pharma has hailed a year of progress as it released its first full year results since its AIM-listing last March.

Despite pre-tax losses more than doubling from £4.3m to £8.8m, founder and chief executive Dr Neil Murray said the board is “very confident” in the prospects for the business.

“We’ve made fantastic progress across the pipeline, it’s really maturing very well and we expect four of our programmes to be in clinical trials by the end of 2016 or early 2017.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.